DE68927459T2 - Nachweis einer neurologischen Krankheit oder einer Funktionsstörung - Google Patents

Nachweis einer neurologischen Krankheit oder einer Funktionsstörung

Info

Publication number
DE68927459T2
DE68927459T2 DE68927459T DE68927459T DE68927459T2 DE 68927459 T2 DE68927459 T2 DE 68927459T2 DE 68927459 T DE68927459 T DE 68927459T DE 68927459 T DE68927459 T DE 68927459T DE 68927459 T2 DE68927459 T2 DE 68927459T2
Authority
DE
Germany
Prior art keywords
disease
nptp
dysfunction
neurological
evidence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68927459T
Other languages
English (en)
Other versions
DE68927459D1 (de
Inventor
Jack R Wands
Jerome Gross
Mehmet Ozturk
La Monte Suzanne De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE68927459D1 publication Critical patent/DE68927459D1/de
Publication of DE68927459T2 publication Critical patent/DE68927459T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE68927459T 1988-12-21 1989-12-21 Nachweis einer neurologischen Krankheit oder einer Funktionsstörung Expired - Lifetime DE68927459T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28720788A 1988-12-21 1988-12-21
US45197589A 1989-12-20 1989-12-20

Publications (2)

Publication Number Publication Date
DE68927459D1 DE68927459D1 (de) 1996-12-19
DE68927459T2 true DE68927459T2 (de) 1997-04-24

Family

ID=26964334

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68927459T Expired - Lifetime DE68927459T2 (de) 1988-12-21 1989-12-21 Nachweis einer neurologischen Krankheit oder einer Funktionsstörung

Country Status (10)

Country Link
US (1) US6071705A (de)
EP (1) EP0378924B1 (de)
JP (1) JP3309972B2 (de)
AT (1) ATE145285T1 (de)
AU (3) AU4837990A (de)
CA (1) CA2006332C (de)
DE (1) DE68927459T2 (de)
ES (1) ES2094733T3 (de)
GR (1) GR3022287T3 (de)
WO (1) WO1990006993A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DK1564293T3 (da) * 1993-04-20 2009-01-12 Gen Hospital Corp Nervetrådproteingenekspression og detektion af Alzheimers sygdom
US20030033621A1 (en) * 1997-02-26 2003-02-13 De La Monte Suzanne Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
AU749348B2 (en) 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
US6342350B1 (en) 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
GB9719796D0 (en) * 1997-09-17 1997-11-19 Medical Res Council Medicament
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
AU2002304314B2 (en) * 2001-03-08 2007-09-06 Nyomox Pharmaceutical Corporation Using neural thread proteins to treat tumors and other hyperproliferative disorders
AU2002308327B2 (en) * 2001-05-04 2006-11-30 Nymox Corporation Method of preventing cell death using antibodies to neural thread proteins
EP1392347B1 (de) * 2001-05-16 2005-08-03 Nymox Corporation Prävention des zelltodes durch verwendung der segmente der neurofilamentproteine
DK1390403T3 (da) * 2001-05-25 2007-05-14 Nymox Corp Peptider afledt af nervetrådsproteiner og medicinsk anvendelse deraf
DE60218179T2 (de) * 2001-07-19 2007-11-22 Nymox Corp., Saint-Laurent Peptide zur behandlung von tumoren und anderen bedingungen, die die entfernung oder zerstörung von zellen erfordern
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CA2483635A1 (en) * 2002-04-25 2003-11-06 Alon Shalev Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7636597B2 (en) * 2002-11-14 2009-12-22 Brainsgate, Ltd. Surgical tools and techniques for stimulation
GB0223187D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Screen
AU2004229317B2 (en) * 2003-03-31 2012-01-12 University Of Florida Research Foundation, Inc. Assessing neuronal damage from blood samples
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US7943046B2 (en) * 2004-10-01 2011-05-17 Agilent Technologies, Inc Methods and systems for on-column protein delipidation
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
ATE514950T1 (de) 2007-09-07 2011-07-15 Univ Zuerich Verfahren zur untersuchung von sepsis bei menschen
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4816388A (en) * 1985-10-30 1989-03-28 Children's Medical Center Corporation Human prealbumin and related methods and products
FR2661187B1 (fr) * 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.

Also Published As

Publication number Publication date
GR3022287T3 (en) 1997-04-30
ES2094733T3 (es) 1997-02-01
US6071705A (en) 2000-06-06
JPH04502364A (ja) 1992-04-23
ATE145285T1 (de) 1996-11-15
DE68927459D1 (de) 1996-12-19
EP0378924B1 (de) 1996-11-13
EP0378924A2 (de) 1990-07-25
WO1990006993A1 (en) 1990-06-28
EP0378924A3 (de) 1991-11-06
AU5265393A (en) 1994-03-17
CA2006332C (en) 2003-04-08
AU4837990A (en) 1990-07-10
AU641376B2 (en) 1993-09-23
JP3309972B2 (ja) 2002-07-29
CA2006332A1 (en) 1990-06-21

Similar Documents

Publication Publication Date Title
DE68927459D1 (de) Nachweis einer neurologischen Krankheit oder einer Funktionsstörung
DE69633973D1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
NO972024L (no) Metoder for diagnostisering av glaukom
ATE114672T1 (de) Peptidzusammensetzung und verfahren zum nachweis von antikörpern gegen htlv-iii.
EP0261224A4 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE69127487T2 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
DE3587542D1 (de) Verfahren zur Diagnose in vitro von menschlichen Cytomegalovirusinfektionen und Anwendung von monoklonalen Antikörpern gegen Cytomegaloviren, die mit einer cytomegalovirusinduzierten Proteinkinase reagieren.
DE69031726D1 (de) Antikörper, ihre Herstellung und Verwendung
ATE104355T1 (de) Nachweis eines mit atmungskrankheiten verbundenen einzelstammes von chlamydia.
BE888855A (fr) Procede d'obtention de preparations de toxoplasmes pour le diagnostic de la toxoplasmose, et preparations ainsi obtenues
DE3650635D1 (de) Monoklonale Antikörper
ATE86261T1 (de) Tumorassoziiertes antigen.
IT1239719B (it) Uso dell'anticorpo monoclonale sp-2 nella diagnostica clinica ed il monitoraggio del progredire dell'infezione hiv
RU95101284A (ru) Способ диагностики инфаркта кишечника
ATE146597T1 (de) Verfahren zur diagnose von hiv-infektionen
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis
NO177310C (no) Antigent polypeptid fra HBxAg, antistoff som reagerer med polypeptidet, diagnostisk analysesystem for bestemmelse av tilstedeværelsen av HBxAg i en kroppspröve, samt anvendelse av polypeptidet til in vitro diagnose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition